Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: A retrospective study

C. Bengala, C. Zamagni, P. Pedrazzoli, P. Matteucci, A. Ballestrero, G. Da Prada, M. Martino, G. Rosti, M. Danova, M. Bregni, G. Jovic, V. Guarneri, M. Maur, P. F. Conte

Research output: Contribution to journalArticlepeer-review

Abstract

HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MBC) patients treated with high-dose chemotherapy (HDC). HER-2 status is also a predictive factor and when trastuzumab is administered in combination with or sequentially to chemotherapy, a significant disease-free and/or overall survival improvement has been observed in HER-2 + early and MBC. Unfortunately, in both settings, trastuzumab is associated with an increased risk of cardiac dysfunction (CD). We have reviewed the clinical charts of HER-2-overexpressing MBC patients treated with trastuzumab after HDC. Age, baseline left ventricular ejection fraction (LVEF), radiation therapy on cardiac area, exposure to anthracycline, single or multiple transplant, high-dose agents, trastuzumab treatment duration were recorded as potential risk factors. In total, 53 patients have been included in the analysis. Median LVEF at baseline was 60.5%; at the end of trastuzumab (data available for 28 patients only), it was 55% (P = 0.01). Five out of the 28 (17.9%) patients experienced CD. Two out of 53 (3.8%) patients developed a congestive heart failure. Age ≥50 years and multiple transplant procedure were potential risk factors for CD. The overall incidence of CD observed in this population of HER-2+ MBC patients treated with trastuzumab after HDC is not superior to that reported with concomitant trastuzumab and anthracyclines. However, patients with age ≥50 years or receiving multiple course of HDC should be considered at risk for CD.

Original languageEnglish
Pages (from-to)1016-1020
Number of pages5
JournalBritish Journal of Cancer
Volume94
Issue number7
DOIs
Publication statusPublished - Apr 10 2006

Keywords

  • Cardiac toxicity
  • High-dose chemotherapy
  • Metastatic breast cancer
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: A retrospective study'. Together they form a unique fingerprint.

Cite this